IPL 423088
Alternative Names: IPL 4088Latest Information Update: 02 Aug 2004
At a glance
- Originator Inflazyme Pharmaceuticals
- Class Anti-inflammatories; Antiasthmatics
- Mechanism of Action Type 4 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Asthma; Inflammatory bowel diseases
Most Recent Events
- 02 Aug 2004 Discontinued - Preclinical for Asthma in Canada (PO)
- 02 Aug 2004 Discontinued - Preclinical for Inflammatory bowel disease in Canada (PO)
- 26 Feb 2003 No development reported - Preclinical for Asthma in Canada (PO)